Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > DCs and NK cells as the enhancer of OVs

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 12, 2023 4:19pm

200 Views

Post# 35219551

RE:DCs and NK cells as the enhancer of OVs

"... OVs have the advantage of “warming up” immunologically cold tumors to the level of an immunologically activated malignancy ..."

"... Additionally, it has been discovered that by encouraging dendritic cell maturation and the polarization of macrophages to the M1 phenotype, the OV@NK system can alleviate immunosuppression in the TME.

Both in vitro and in vivo investigations have shown that Ad@NKs have exceptional anticancer and antimetastatic qualities. These features are evidenced by the killing of tumor cells, the activation of immunogenic cell death, and the immunomodulation of the TME (173). The DC is also capable of delivering oncolytic reoviruses ... when DCs were loaded with reovirus, strong anti-tumor as well as anti-viral immune responses were observed. This resulted in an increased survival rate of mice who had melanoma. ...

Hence, using immune cells like DCs as cell carriers offers a way to improve the systemic dispersion of OVs to target primary and metastatic tumors. This is particularly useful for OVs against which it is anticipated that the host already possesses anti-viral immunity as a result of prior exposure. (177)."

<< Previous

Bullboard Posts

Next >>

Three high-conviction small-cap stocks across the risk spectrum